Thoratec Corp (THOR) 43.00 $THOR
Thoratec Announced Study Results, Time To Book Profit?
Andy Batts - at Seeking Alpha - Wed Apr 22, 7:34AM CDT
THOR: 43.00 (-0.76), HTWR: 77.60 (-2.35)
Thoratec Schedules First Quarter Conference Call, Webcast
PR Newswire - Mon Apr 20, 8:10AM CDT
Thoratec Corporation (NASDAQ: THOR), a world leader in device-based mechanical circulatory support therapies to save, support and restore failing hearts, today announced that it will report its operating results for the first quarter of fiscal year 2015 on Thursday, May 7.
THOR: 43.00 (-0.76)
Thoratec's HeartMate II Scores High in ENDURANCE Trial - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Apr 17, 4:35PM CDT
Thoratec Corp. (THOR) recently presented positive data for its HeartMate II heart pump device from the ENDURANCE destination therapy trial.
CAPR: 7.50 (+0.76), SRDX: 26.57 (+0.02), LMAT: 8.44 (-0.10), THOR: 43.00 (-0.76)
ROADMAP Study Demonstrates HeartMate II® Benefits In Ambulatory Advanced Heart Failure Patients
PR Newswire - Fri Apr 17, 2:30AM CDT
Thoratec Corporation (NASDAQ: THOR), a world leader in device-based mechanical circulatory support therapies to save, support and restore failing hearts, today announced results from the ROADMAP Study (Risk Assessment and Comparative Effectiveness of Left Ventricular Assist Device and Medical Management in Ambulatory Heart Failure Patients). For the primary endpoint, a composite of survival and functional improvement, ROADMAP demonstrated a statistically significant benefit of HeartMate II LVAD support relative to optimal medical management in ambulatory NYHA Class IIIB/IV (INTERMACS profile 4-7) heart failure patients. One-year study results were presented today during the 35th Annual Meeting and Scientific Sessions of the International Society for Heart and Lung Transplantation (ISHLT 2015) in Nice, France.
THOR: 43.00 (-0.76)
ROADMAP Study Demonstrating Benefits of HeartMate II(R) Left Ventricular Assist Device Presented at ISHLT Conference
Marketwired - Fri Apr 17, 2:10AM CDT
Today at the 35th Annual International Society for Heart and Lung Transplantation (ISHLT) Meeting & Scientific Sessions, researchers presented one-year results from the ROADMAP Study (Risk Assessment and Comparative Effectiveness of Left Ventricular Assist Device and Medical Management in Ambulatory Heart Failure Patients). The study evaluated the effects of Thoratec Corporation's (NASDAQ: THOR) HeartMate II® Left Ventricular Assist Device (LVAD) compared with optimal medical management patients. Results from the multi-center, non-randomized, controlled, observational study indicate that the HeartMate II enhanced the long-term outcomes of patients with advanced heart failure. One-year survival rate was 80 percent in the HeartMate II group, compared with 64 percent for medically managed patients on an as-treated basis.
THOR: 43.00 (-0.76)
Thoratec Up 46.5% Since SmarTrend Uptrend Call (THOR)
Comtex SmarTrend(R) - Thu Apr 16, 11:21AM CDT
SmarTrend identified an Uptrend for Thoratec (NASDAQ:THOR) on November 17th, 2014 at $30.00. In approximately 5 months, Thoratec has returned 46.47% as of today's recent price of $43.94.
THOR: 43.00 (-0.76)
Thoratec Hits 52-Week High on Favorable Developments - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 16, 10:20AM CDT
Shares of Thoratec Corp (THOR) scaled a new 52-week high of $43.24 in mid-day trading on Apr 15.
ABMD: 69.31 (-0.40), FLDM: 43.04 (-1.36), INGN: 36.39 (-0.04), THOR: 43.00 (-0.76)
Thoratec Comments On HeartMate II® Data In ENDURANCE Destination Therapy Trial
PR Newswire - Thu Apr 16, 8:49AM CDT
Thoratec Corporation (NASDAQ: THOR), a world leader in device-based mechanical circulatory support therapies to save, support and restore failing hearts, commented on HeartMate II clinical data presented as part of the ENDURANCE destination therapy trial today at the 35th Annual Meeting and Scientific Sessions of the International Society for Heart and Lung Transplantation (ISHLT 2015) in Nice, France.
THOR: 43.00 (-0.76)
HeartWare Gets VAD Distribution Approval from Health Canada - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Apr 15, 12:00PM CDT
HeartWare International Inc. (HTWR) recently received approval from Health Canada to market its HVAD as a bridge to heart transplantation in patients with end-stage heart failure conditions.
ABMD: 69.31 (-0.40), THOR: 43.00 (-0.76), LMNX: 16.34 (-0.01), HTWR: 77.60 (-2.35)
Insider Trading Alert - THOR, GMAN And INO Traded By Insiders
at The Street - Tue Apr 14, 10:00AM CDT
Stocks with insider trader activity include THOR, GMAN and INO
INO: 10.39 (-0.09), GMAN: 8.63 (-0.17), THOR: 43.00 (-0.76)
Thoratec Has Returned 41.4% Since SmarTrend Recommendation (THOR)
Comtex SmarTrend(R) - Thu Apr 09, 10:01AM CDT
SmarTrend identified an Uptrend for Thoratec (NASDAQ:THOR) on November 17th, 2014 at $30.00. In approximately 5 months, Thoratec has returned 41.40% as of today's recent price of $42.42.
THOR: 43.00 (-0.76)
Thoratec Wins FDA Consent to Expand HeartMate III US Trial - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Apr 06, 10:10AM CDT
With this approval, Thoratec Corp. (THOR) can now extend the HeartMate III U.S. IDE clinical trial at up to 60 sites across the country from the initial limited enrollment phase at 5 sites.
ABMD: 69.31 (-0.40), INGN: 36.39 (-0.04), EW: 140.87 (+0.39), THOR: 43.00 (-0.76)
Thoratec To Webcast Investor Meeting At ISHLT Conference
PR Newswire - Mon Apr 06, 7:45AM CDT
Thoratec Corporation (NASDAQ: THOR), a world leader in device-based mechanical circulatory support therapies to save, support and restore failing hearts, today announced that it will hold a meeting for investors and analysts during the ISHLT 2015 Conference in Nice, France on Friday, April 17.
THOR: 43.00 (-0.76)
Thoratec announces FDA approval to expand HeartMate III US clinical trial
M2 - Thu Apr 02, 10:49AM CDT
Thoratec Corporation (NASDAQ: THOR), a provider of device-based mechanical circulatory support therapies to save, support and restore failing hearts, revealed on Friday that it has been given final approval from the FDA to increase enrollment to up to 1,028 patients in up to 60 sites for the HeartMate III US clinical trial.
THOR: 43.00 (-0.76)
Thoratec Receives Approval From FDA For Full Expansion Of HeartMate III(TM) U.S. IDE Clinical Trial
PR Newswire - Thu Apr 02, 8:00AM CDT
Thoratec Corporation (NASDAQ: THOR), a world leader in device-based mechanical circulatory support therapies to save, support and restore failing hearts, today announced that it received final approval from the FDA to broaden enrollment of the HeartMate III U.S. clinical trial of up to 1,028 patients in up to 60 sites. This was based on the FDA's evaluation of safety data from the first ten HeartMate III implants performed in recent months during a limited enrollment phase at five sites.
THOR: 43.00 (-0.76)
Thoratec Shares Up 35.4% Since SmarTrend's Buy Recommendation (THOR)
Comtex SmarTrend(R) - Wed Mar 25, 10:10AM CDT
SmarTrend identified an Uptrend for Thoratec (NASDAQ:THOR) on November 17th, 2014 at $30.00. In approximately 4 months, Thoratec has returned 35.43% as of today's recent price of $40.63.
THOR: 43.00 (-0.76)
South Africa Heart Valve and Repair Market Analysis 2015-2020
M2 - Thu Mar 19, 9:51AM CDT
Research and Markets (http://www.researchandmarkets.com/research/slpqjq/south_africa) has announced the addition of the "South Africa Heart Valve and Repair Market Analysis - Size, Share, Growth, Trends and Forecast Through 2007 - 2020" report to their offering. This research report provides key market trends, market forecasts and competitive scenario of the cardiovascular heart valve and repair in South Africa through 2020. The product categories covered in this report include: - Heart Valve - Annuloplasty Rings Scope The report highlights historic and forecasted market size in terms of revenues & unit sales, average selling price, growth rates, and company market shares. - Highlights and compares key product categories for growth trends and revenue forecast. - Market size, annualized revenue and unit sales for each product category from 2007 to 2020. - Cross category comparison - Growth and revenue comparison for product categories, historic and forecast through 2020. - Market share of companies. - Average selling price ($) for each product type (2007 to 2020). - Recent Events and Developments. Key Topics Covered: 1. Tables & Charts 2. Introduction 3. Scope of the Report 4. South Africa Market for Cardiovascular Heart Valve and Repair, 2007-2020 5. Recent Events and Developments 6. Appendix Companies Mentioned - Edwards Lifesciences Corporation - Maquet - Medtronic, Inc. - Sorin Group - St. Jude Medical Inc. - Thoratec Corporation For more information visit http://www.researchandmarkets.com/research/sl...uth_africa
MDT: 78.01 (+0.93), STJ: 73.55 (+4.43), EW: 140.87 (+0.39), THOR: 43.00 (-0.76)
Thoratec Announced Study Results, Time To Book Profit?
Andy Batts - at Seeking Alpha - Wed Apr 22, 7:34AM CDT
THOR: 43.00 (-0.76), HTWR: 77.60 (-2.35)
Thoratec Schedules First Quarter Conference Call, Webcast
PR Newswire - Mon Apr 20, 8:10AM CDT
Thoratec Corporation (NASDAQ: THOR), a world leader in device-based mechanical circulatory support therapies to save, support and restore failing hearts, today announced that it will report its operating results for the first quarter of fiscal year 2015 on Thursday, May 7.
THOR: 43.00 (-0.76)
Thoratec's HeartMate II Scores High in ENDURANCE Trial - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Apr 17, 4:35PM CDT
Thoratec Corp. (THOR) recently presented positive data for its HeartMate II heart pump device from the ENDURANCE destination therapy trial.
CAPR: 7.50 (+0.76), SRDX: 26.57 (+0.02), LMAT: 8.44 (-0.10), THOR: 43.00 (-0.76)
ROADMAP Study Demonstrates HeartMate II® Benefits In Ambulatory Advanced Heart Failure Patients
PR Newswire - Fri Apr 17, 2:30AM CDT
Thoratec Corporation (NASDAQ: THOR), a world leader in device-based mechanical circulatory support therapies to save, support and restore failing hearts, today announced results from the ROADMAP Study (Risk Assessment and Comparative Effectiveness of Left Ventricular Assist Device and Medical Management in Ambulatory Heart Failure Patients). For the primary endpoint, a composite of survival and functional improvement, ROADMAP demonstrated a statistically significant benefit of HeartMate II LVAD support relative to optimal medical management in ambulatory NYHA Class IIIB/IV (INTERMACS profile 4-7) heart failure patients. One-year study results were presented today during the 35th Annual Meeting and Scientific Sessions of the International Society for Heart and Lung Transplantation (ISHLT 2015) in Nice, France.
THOR: 43.00 (-0.76)
ROADMAP Study Demonstrating Benefits of HeartMate II(R) Left Ventricular Assist Device Presented at ISHLT Conference
Marketwired - Fri Apr 17, 2:10AM CDT
Today at the 35th Annual International Society for Heart and Lung Transplantation (ISHLT) Meeting & Scientific Sessions, researchers presented one-year results from the ROADMAP Study (Risk Assessment and Comparative Effectiveness of Left Ventricular Assist Device and Medical Management in Ambulatory Heart Failure Patients). The study evaluated the effects of Thoratec Corporation's (NASDAQ: THOR) HeartMate II® Left Ventricular Assist Device (LVAD) compared with optimal medical management patients. Results from the multi-center, non-randomized, controlled, observational study indicate that the HeartMate II enhanced the long-term outcomes of patients with advanced heart failure. One-year survival rate was 80 percent in the HeartMate II group, compared with 64 percent for medically managed patients on an as-treated basis.
THOR: 43.00 (-0.76)
Thoratec Up 46.5% Since SmarTrend Uptrend Call (THOR)
Comtex SmarTrend(R) - Thu Apr 16, 11:21AM CDT
SmarTrend identified an Uptrend for Thoratec (NASDAQ:THOR) on November 17th, 2014 at $30.00. In approximately 5 months, Thoratec has returned 46.47% as of today's recent price of $43.94.
THOR: 43.00 (-0.76)
Thoratec Hits 52-Week High on Favorable Developments - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 16, 10:20AM CDT
Shares of Thoratec Corp (THOR) scaled a new 52-week high of $43.24 in mid-day trading on Apr 15.
ABMD: 69.31 (-0.40), FLDM: 43.04 (-1.36), INGN: 36.39 (-0.04), THOR: 43.00 (-0.76)
Thoratec Comments On HeartMate II® Data In ENDURANCE Destination Therapy Trial
PR Newswire - Thu Apr 16, 8:49AM CDT
Thoratec Corporation (NASDAQ: THOR), a world leader in device-based mechanical circulatory support therapies to save, support and restore failing hearts, commented on HeartMate II clinical data presented as part of the ENDURANCE destination therapy trial today at the 35th Annual Meeting and Scientific Sessions of the International Society for Heart and Lung Transplantation (ISHLT 2015) in Nice, France.
THOR: 43.00 (-0.76)
HeartWare Gets VAD Distribution Approval from Health Canada - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Apr 15, 12:00PM CDT
HeartWare International Inc. (HTWR) recently received approval from Health Canada to market its HVAD as a bridge to heart transplantation in patients with end-stage heart failure conditions.
ABMD: 69.31 (-0.40), THOR: 43.00 (-0.76), LMNX: 16.34 (-0.01), HTWR: 77.60 (-2.35)
Insider Trading Alert - THOR, GMAN And INO Traded By Insiders
at The Street - Tue Apr 14, 10:00AM CDT
Stocks with insider trader activity include THOR, GMAN and INO
INO: 10.39 (-0.09), GMAN: 8.63 (-0.17), THOR: 43.00 (-0.76)
Thoratec Has Returned 41.4% Since SmarTrend Recommendation (THOR)
Comtex SmarTrend(R) - Thu Apr 09, 10:01AM CDT
SmarTrend identified an Uptrend for Thoratec (NASDAQ:THOR) on November 17th, 2014 at $30.00. In approximately 5 months, Thoratec has returned 41.40% as of today's recent price of $42.42.
THOR: 43.00 (-0.76)
Thoratec Wins FDA Consent to Expand HeartMate III US Trial - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Apr 06, 10:10AM CDT
With this approval, Thoratec Corp. (THOR) can now extend the HeartMate III U.S. IDE clinical trial at up to 60 sites across the country from the initial limited enrollment phase at 5 sites.
ABMD: 69.31 (-0.40), INGN: 36.39 (-0.04), EW: 140.87 (+0.39), THOR: 43.00 (-0.76)
Thoratec To Webcast Investor Meeting At ISHLT Conference
PR Newswire - Mon Apr 06, 7:45AM CDT
Thoratec Corporation (NASDAQ: THOR), a world leader in device-based mechanical circulatory support therapies to save, support and restore failing hearts, today announced that it will hold a meeting for investors and analysts during the ISHLT 2015 Conference in Nice, France on Friday, April 17.
THOR: 43.00 (-0.76)
Thoratec announces FDA approval to expand HeartMate III US clinical trial
M2 - Thu Apr 02, 10:49AM CDT
Thoratec Corporation (NASDAQ: THOR), a provider of device-based mechanical circulatory support therapies to save, support and restore failing hearts, revealed on Friday that it has been given final approval from the FDA to increase enrollment to up to 1,028 patients in up to 60 sites for the HeartMate III US clinical trial.
THOR: 43.00 (-0.76)
Thoratec Receives Approval From FDA For Full Expansion Of HeartMate III(TM) U.S. IDE Clinical Trial
PR Newswire - Thu Apr 02, 8:00AM CDT
Thoratec Corporation (NASDAQ: THOR), a world leader in device-based mechanical circulatory support therapies to save, support and restore failing hearts, today announced that it received final approval from the FDA to broaden enrollment of the HeartMate III U.S. clinical trial of up to 1,028 patients in up to 60 sites. This was based on the FDA's evaluation of safety data from the first ten HeartMate III implants performed in recent months during a limited enrollment phase at five sites.
THOR: 43.00 (-0.76)
Thoratec Shares Up 35.4% Since SmarTrend's Buy Recommendation (THOR)
Comtex SmarTrend(R) - Wed Mar 25, 10:10AM CDT
SmarTrend identified an Uptrend for Thoratec (NASDAQ:THOR) on November 17th, 2014 at $30.00. In approximately 4 months, Thoratec has returned 35.43% as of today's recent price of $40.63.
THOR: 43.00 (-0.76)
South Africa Heart Valve and Repair Market Analysis 2015-2020
M2 - Thu Mar 19, 9:51AM CDT
Research and Markets (http://www.researchandmarkets.com/research/slpqjq/south_africa) has announced the addition of the "South Africa Heart Valve and Repair Market Analysis - Size, Share, Growth, Trends and Forecast Through 2007 - 2020" report to their offering. This research report provides key market trends, market forecasts and competitive scenario of the cardiovascular heart valve and repair in South Africa through 2020. The product categories covered in this report include: - Heart Valve - Annuloplasty Rings Scope The report highlights historic and forecasted market size in terms of revenues & unit sales, average selling price, growth rates, and company market shares. - Highlights and compares key product categories for growth trends and revenue forecast. - Market size, annualized revenue and unit sales for each product category from 2007 to 2020. - Cross category comparison - Growth and revenue comparison for product categories, historic and forecast through 2020. - Market share of companies. - Average selling price ($) for each product type (2007 to 2020). - Recent Events and Developments. Key Topics Covered: 1. Tables & Charts 2. Introduction 3. Scope of the Report 4. South Africa Market for Cardiovascular Heart Valve and Repair, 2007-2020 5. Recent Events and Developments 6. Appendix Companies Mentioned - Edwards Lifesciences Corporation - Maquet - Medtronic, Inc. - Sorin Group - St. Jude Medical Inc. - Thoratec Corporation For more information visit http://www.researchandmarkets.com/research/sl...uth_africa
MDT: 78.01 (+0.93), STJ: 73.55 (+4.43), EW: 140.87 (+0.39), THOR: 43.00 (-0.76)
